Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma

详细信息    查看全文

• 作者：Dharshan Sivaraj¹ ; ^{Dharshan.sivaraj@duke.edu} ; Michael M. Green¹ ; Zhiguo Li² ; Anthony D. Sung¹ ; Stefanie Sarantopoulos¹ ; Yubin Kang¹ ; Gwynn D. Long¹ ; Mitchell E. Horwitz¹ ; Richard D. Lopez¹ ; Keith M. Sullivan¹ ; David A. Rizzieri¹ ; Nelson J. Chao¹ ; Cristina Gasparetto¹
• 关键词：Multiple myeloma ; Maintenance therapy ; Bortezomib ; Autologous stem cell transplantation
• 刊名：Biology of Blood and Marrow Transplantation
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：23
• 期：2
• 页码：262-268
• 全文大小：744 K
• 卷排序：23

文摘

We conducted a retrospective review analyzing outcomes of maintenance therapy with bortezomib after autologous stem cell transplantation A total of 102 patients treated from 2005 to 2015 were analyzed Two percent of patients required discontinuation of bortezomib maintenance because of adverse events Bortezomib in the maintenance setting is well tolerated and efficacious, and it can be continued without evidence of secondary malignancy until disease progression